RARA and neoplasm: Blocking PD-1/PD-L1 increased all-trans retinoic acid (ATRA) and type I IFN in the treatment-sensitive TME, which leads to activation of the retinoic acid receptor alpha (RAR-α) and subsequently CD38 expression on tumor cells.